In:
Therapeutic Advances in Psychopharmacology, SAGE Publications, Vol. 4, No. 6 ( 2014-12), p. 228-239
Abstract:
Rates of discontinuation of antipsychotic treatment for patients with schizophrenia are high and evidence is limited by selective inclusion and high attrition in randomized controlled trials. Aims To study time to discontinuation of antipsychotic treatment for patients with schizophrenia. Method All patients with schizophrenia ( n = 396) discharged between 2005 and 2011 were followed until discontinuation (clinician or patient decided) of antipsychotic treatment or other endpoints. Univariate and multivariate survival analyses (with time on antipsychotic treatment as the dependent variable) using time-dependent variables were performed. Results Clozapine displayed lower risk for all-cause ( p 〈 0.001), clinician-decided ( p = 0.012) and patient-decided ( p = 0.039) discontinuation versus olanzapine oral treatment in the multivariate Cox regression. Second-generation long-acting injection antipsychotics (LAI) ( p = 0.015) and first-generation long-acting injection antipsychotics ( p = 0.013) showed significantly lower risks for patient-decided discontinuation than olanzapine oral. Conclusion Higher effectiveness of clozapine and LAI treatment versus oral olanzapine were identified in a clinical cohort of patients with schizophrenia.
Type of Medium:
Online Resource
ISSN:
2045-1253
,
2045-1261
DOI:
10.1177/2045125314545614
Language:
English
Publisher:
SAGE Publications
Publication Date:
2014
detail.hit.zdb_id:
2646542-5
